149 related articles for article (PubMed ID: 32931681)
1. Specific Biomarker Expression Patterns in the Diagnosis of Residual and Recurrent Endometrial Precancers After Progestin Treatment: A Longitudinal Study.
Chen H; Lucas E; Strickland AL; Carrick K; Gwin K; Castrillon DH; Rivera-Colon G; Niu S; Molberg KH; Zheng W
Am J Surg Pathol; 2020 Oct; 44(10):1429-1439. PubMed ID: 32931681
[TBL] [Abstract][Full Text] [Related]
2. Reliable Identification of Endometrial Precancers Through Combined Pax2, β-Catenin, and Pten Immunohistochemistry.
Aguilar M; Chen H; Rivera-Colon G; Niu S; Carrick K; Gwin K; Cuevas IC; Sahoo SS; Li HD; Zhang S; Zheng W; Lucas E; Castrillon DH
Am J Surg Pathol; 2022 Mar; 46(3):404-414. PubMed ID: 34545858
[TBL] [Abstract][Full Text] [Related]
3. Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia.
Ørbo A; Arnes M; Lyså LM; Straume B
Anticancer Res; 2015 Dec; 35(12):6401-9. PubMed ID: 26637849
[TBL] [Abstract][Full Text] [Related]
4. Utility of a PAX2, PTEN, and β-catenin Panel in the Diagnosis of Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia in Endometrial Polyps.
Lucas E; Niu S; Aguilar M; Molberg K; Carrick K; Rivera-Colon G; Gwin K; Wang Y; Zheng W; Castrillon DH; Chen H
Am J Surg Pathol; 2023 Sep; 47(9):1019-1026. PubMed ID: 37314146
[TBL] [Abstract][Full Text] [Related]
5. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.
Allison KH; Upson K; Reed SD; Jordan CD; Newton KM; Doherty J; Swisher EM; Garcia RL
Int J Gynecol Pathol; 2012 Mar; 31(2):151-159. PubMed ID: 22317873
[TBL] [Abstract][Full Text] [Related]
6. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
[TBL] [Abstract][Full Text] [Related]
7. Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia.
Quddus MR; Ologun BA; Sung CJ; Steinhoff MM; Lawrence WD
Int J Gynecol Pathol; 2009 Sep; 28(5):471-6. PubMed ID: 19696618
[TBL] [Abstract][Full Text] [Related]
8. Histopathologic diagnosis of endometrial precancers: Updates and future directions.
Chen H; Strickland AL; Castrillon DH
Semin Diagn Pathol; 2022 May; 39(3):137-147. PubMed ID: 34920905
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.
Upson K; Allison KH; Reed SD; Jordan CD; Newton KM; Swisher EM; Doherty JA; Garcia RL
Am J Obstet Gynecol; 2012 Jul; 207(1):36.e1-8. PubMed ID: 22727345
[TBL] [Abstract][Full Text] [Related]
10. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer.
Monte NM; Webster KA; Neuberg D; Dressler GR; Mutter GL
Cancer Res; 2010 Aug; 70(15):6225-32. PubMed ID: 20631067
[TBL] [Abstract][Full Text] [Related]
11. Pax2 expression in simultaneously diagnosed WHO and EIN classification systems.
Joiner AK; Quick CM; Jeffus SK
Int J Gynecol Pathol; 2015 Jan; 34(1):40-6. PubMed ID: 25473752
[TBL] [Abstract][Full Text] [Related]
12. Predicting Progestin Therapy Response With PTEN, PAX2, and β-Catenin in Patients With Endometrioid Precancer.
Liu N; Lin W; Wang Y; Yao Z; Rivera-Colon G; Li Y; Carrick KS; Chen H; Lucas E; Zheng W
Int J Gynecol Pathol; 2024 Jan; ():. PubMed ID: 38293998
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Importance of PAX2, ARID1A, and FOXA1 Biomarkers in Atypical Endometrial Hyperplasia.
Yildiz ON; Topal CS; Zemheri IE
J Coll Physicians Surg Pak; 2023 Aug; 33(8):847-851. PubMed ID: 37553920
[TBL] [Abstract][Full Text] [Related]
14. BCL-2 and PAX2 Expressions in EIN which Had Been Previously Diagnosed as Non-Atypical Hyperplasia.
Trabzonlu L; Muezzinoglu B; Corakci A
Pathol Oncol Res; 2019 Apr; 25(2):471-476. PubMed ID: 29270778
[TBL] [Abstract][Full Text] [Related]
15. PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia: A systematic review and meta-analysis of diagnostic accuracy.
Raffone A; Travaglino A; Saccone G; Mascolo M; Insabato L; Mollo A; De Placido G; Zullo F
Acta Obstet Gynecol Scand; 2019 Mar; 98(3):287-299. PubMed ID: 30511741
[TBL] [Abstract][Full Text] [Related]
16. Assessing the prognostic value of PAX2 and PTEN in endometrial carcinogenesis.
Rewcastle E; Varhaugvik AE; Gudlaugsson E; Steinbakk A; Skaland I; van Diermen B; Baak JP; Janssen EAM
Endocr Relat Cancer; 2018 Dec; 25(12):981-991. PubMed ID: 30400021
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
Sletten ET; Arnes M; Lysa LM; Moe BT; Straume B; Orbo A
Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
[TBL] [Abstract][Full Text] [Related]
19. Involution of PTEN-null endometrial glands with progestin therapy.
Zheng W; Baker HE; Mutter GL
Gynecol Oncol; 2004 Mar; 92(3):1008-13. PubMed ID: 14984979
[TBL] [Abstract][Full Text] [Related]
20. Regression of latent endometrial precancers by progestin infiltrated intrauterine device.
Ørbo A; Rise CE; Mutter GL
Cancer Res; 2006 Jun; 66(11):5613-7. PubMed ID: 16740697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]